PRospective Observational registry evaluating the Safety and Effectiveness of Orsiro Stent in Chilean patients - ROSES registry. | PRospective Observational Registry Evaluating the Safety and Effectivenessof Orsiro Stent in Chilean Patients - ROSES Registry.
PRospective Observational registry evaluating the Safety and Effectiveness of Orsiro Stent in Chilean patients - ROSES registry. PRospective Observational Registry Evaluating the Safety and Effectivenessof Orsiro Stent in Chilean Patients - ROSES Registry.
- 2022
Available in print through MWHC library: 2002 - present
BACKGROUND: There is little information of the performance of the new generation of stents with bioabsorbable polymers in the Latin-American population. This registry aimed to further validate the safety and efficacy of the Orsiro bioresorbable polymer sirolimus-eluting stent (BPSES) in unselected patients undergoing percutaneous coronary intervention (PCI) in Chilean centers. CONCLUSIONS: The results of the ROSES multicenter registry indicated good clinical outcomes of BPSES Orsiro in all-comers Latin-American patients undergoing PCI, despite the high-risk patients and treated lesions. Copyright (c) 2021 Elsevier Inc. All rights reserved. METHODS: We prospectively enrolled patients undergoing PCI with BPSES in 6 Chilean centers. The primary endpoint was defined as the composite of cardiac death, target vessel related myocardial infarction (MI) and clinically driven target lesion revascularization at 1-year follow-up. RESULTS: From April 2017 to February 2019, n = 520 patients were enrolled in the registry, more frequently male (74.6%), with a mean age of 62.7 +/- 10.8 years-old and a high prevalence of diabetes (40.2%). The clinical presentation was stable angina in 41.1% (n = 214), acute MI in 52.5% (n = 167 [32.1%] ST-elevation MI and n = 106 [20.4%] non-ST-elevation MI) and unstable angina in 6.3% (n = 33). Of 610 treated lesions, 425 (69.7%) were ACC/AHA type B or C lesions. Device and procedural success were achieved in 99.4% and 98.7% of the patients, respectively. The primary endpoint of the study occurred in 4%, primary driven by cardiac death.
English
1878-0938
10.1016/j.carrev.2021.05.022 [doi] S1553-8389(21)00268-2 [pii]
*Cardiovascular Agents
*Coronary Artery Disease
*Drug-Eluting Stents
*Percutaneous Coronary Intervention
*Rosa
Absorbable Implants
Aged
Cardiovascular Agents/ae [Adverse Effects]
Chile
Coronary Artery Disease/th [Therapy]
Drug-Eluting Stents/ae [Adverse Effects]
Humans
Male
Middle Aged
Percutaneous Coronary Intervention/ae [Adverse Effects]
Prosthesis Design
Registries
Time Factors
Treatment Outcome
MedStar Heart & Vascular Institute
Journal Article
Available in print through MWHC library: 2002 - present
BACKGROUND: There is little information of the performance of the new generation of stents with bioabsorbable polymers in the Latin-American population. This registry aimed to further validate the safety and efficacy of the Orsiro bioresorbable polymer sirolimus-eluting stent (BPSES) in unselected patients undergoing percutaneous coronary intervention (PCI) in Chilean centers. CONCLUSIONS: The results of the ROSES multicenter registry indicated good clinical outcomes of BPSES Orsiro in all-comers Latin-American patients undergoing PCI, despite the high-risk patients and treated lesions. Copyright (c) 2021 Elsevier Inc. All rights reserved. METHODS: We prospectively enrolled patients undergoing PCI with BPSES in 6 Chilean centers. The primary endpoint was defined as the composite of cardiac death, target vessel related myocardial infarction (MI) and clinically driven target lesion revascularization at 1-year follow-up. RESULTS: From April 2017 to February 2019, n = 520 patients were enrolled in the registry, more frequently male (74.6%), with a mean age of 62.7 +/- 10.8 years-old and a high prevalence of diabetes (40.2%). The clinical presentation was stable angina in 41.1% (n = 214), acute MI in 52.5% (n = 167 [32.1%] ST-elevation MI and n = 106 [20.4%] non-ST-elevation MI) and unstable angina in 6.3% (n = 33). Of 610 treated lesions, 425 (69.7%) were ACC/AHA type B or C lesions. Device and procedural success were achieved in 99.4% and 98.7% of the patients, respectively. The primary endpoint of the study occurred in 4%, primary driven by cardiac death.
English
1878-0938
10.1016/j.carrev.2021.05.022 [doi] S1553-8389(21)00268-2 [pii]
*Cardiovascular Agents
*Coronary Artery Disease
*Drug-Eluting Stents
*Percutaneous Coronary Intervention
*Rosa
Absorbable Implants
Aged
Cardiovascular Agents/ae [Adverse Effects]
Chile
Coronary Artery Disease/th [Therapy]
Drug-Eluting Stents/ae [Adverse Effects]
Humans
Male
Middle Aged
Percutaneous Coronary Intervention/ae [Adverse Effects]
Prosthesis Design
Registries
Time Factors
Treatment Outcome
MedStar Heart & Vascular Institute
Journal Article